Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.
Mi W, Di X, Wang Y, Li H, Xu X, Li L, Wang H, Wang G, Zhang K, Tian F, Luo J, Yang C, Zhou Y, Xie S, Zhong H, Wu B, Yang D, Chen Z, Li Y, Chen J, Lv S, Yi Q, Jiang Z, Tian J, Zhang H. Mi W, et al. Among authors: jiang z. Transl Psychiatry. 2023 May 10;13(1):163. doi: 10.1038/s41398-023-02435-0. Transl Psychiatry. 2023. PMID: 37164957 Free PMC article. Clinical Trial.
Efficacy and safety of Xian-Lian-Jie-Du optimization decoction as an adjuvant treatment for prevention of recurrence in patients with stage IIIB/IIIC colon cancer: study protocol for a multicentre, randomized controlled trial.
Geng X, Wang Z, Feng L, Gu Y, Wang R, Yao Q, Xu Y, Wu J, Jiang Z, Chen K, Hu W, Tang D, Huo J, Li L, Bu Q, Zhao S, Zhang B, Cheng H. Geng X, et al. Among authors: jiang z. BMC Complement Med Ther. 2023 Jul 17;23(1):239. doi: 10.1186/s12906-023-04052-2. BMC Complement Med Ther. 2023. PMID: 37461034 Free PMC article.
Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial.
Feng GW, Wang ZF, He P, Lan QY, Ni L, Yang YZ, Wang CF, Cui TT, Huang LL, Yan YQ, Jiang ZW, Yang Q, Yu BW, Han X, Chen JJ, Yang SY, Yuan L, Zhou LY, Liu G, Li K, Huang Z, Zhao JC, Hu ZY, Xie ZQ. Feng GW, et al. Among authors: jiang zw. Hum Vaccin Immunother. 2023 Aug;19(2):2262635. doi: 10.1080/21645515.2023.2262635. Epub 2023 Oct 26. Hum Vaccin Immunother. 2023. PMID: 37881130 Free PMC article. Clinical Trial.
Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial.
Zhu D, Hu Y, Jiang Z, Yang T, Chu K, Zhang H, Hu J, Meng X, Tan Z, Wu J, Lian X, Li C, Pan H. Zhu D, et al. Among authors: jiang z. Hum Vaccin Immunother. 2022 Nov 30;18(6):2135929. doi: 10.1080/21645515.2022.2135929. Epub 2022 Nov 28. Hum Vaccin Immunother. 2022. PMID: 36441137 Free PMC article. Clinical Trial.
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.
Al Kaabi N, Yang Y, Eldin Hussein S, Yang T, Abdalla J, Wang H, Lou Z, Chinese Center For Disease Control And Prevention, Bakkour A, Arafat A, China National Biotec Group Company Limited, Jiang Z, Tian Y, National Engineering Technology Research Center For Combined Vaccines Wuhan Institute Of Biological Products Co Ltd, Beijing Institute Of Biological Products Company Limited, Xiao P, Zaher W, Eltantawy I, Wang C, Xu G, Zhang Y, Yang X. Al Kaabi N, et al. Among authors: jiang z. Vaccines (Basel). 2023 Jan 30;11(2):299. doi: 10.3390/vaccines11020299. Vaccines (Basel). 2023. PMID: 36851177 Free PMC article.
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Kaabi NA, Yang YK, Liang Y, Xu K, Zhang XF, Kang Y, Jin YQ, Hou JW, Zhang J, Yang T, Hussein S, ElDein MS, Lei ZH, Zhang H, Shao S, Liu ZM, Liu N, Zheng X, Su JG, Yang SS, Cong X, Tan Y, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Shen FJ, Wu JJ, Han ZB, Du LF, Tang F, Chen S, Ma ZJ, Zheng F, Hou YN, Li XY, Li X, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: jiang z. Signal Transduct Target Ther. 2023 Jan 3;8(1):20. doi: 10.1038/s41392-022-01295-2. Signal Transduct Target Ther. 2023. PMID: 36596779 Free PMC article. Clinical Trial.
Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial.
Liu X, Li Y, Li J, Zhou J, Guo J, Pu Y, Jiang Y, Zhou Y, Jiang Z, Shu Q, Wang C, Wang J, Zhao Y, Zhao W, Wang H, Wei J, Yu H, Gao J, Li X. Liu X, et al. Among authors: jiang z, jiang y. Int J Infect Dis. 2023 Sep;134:53-62. doi: 10.1016/j.ijid.2023.05.017. Epub 2023 May 19. Int J Infect Dis. 2023. PMID: 37211270 Free article. Clinical Trial.
Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
Jin F, Zhu L, Wang Y, Qin G, Tian Y, Xie Y, Jin H, Zhang Y, Wang L, Li J, Wu Z, Sheng Y, Shi L, Yang G, Zhao Z, Chen L, Chen P, Jiang Z, Yu J, Gao Z, Li Q, Wu X, Miao L. Jin F, et al. Among authors: jiang z. Vaccine. 2024 Oct 3;42(23):126059. doi: 10.1016/j.vaccine.2024.06.026. Epub 2024 Jun 27. Vaccine. 2024. PMID: 38937182 Free article. Clinical Trial.
Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].
Jin F, Zhu L, Wang Y, Qin G, Tian Y, Xie Y, Jin H, Zhang Y, Wang L, Li J, Wu Z, Sheng Y, Shi L, Yang G, Zhao Z, Chen L, Chen P, Jiang Z, Yu J, Gao Z, Li Q, Wu X, Miao L. Jin F, et al. Among authors: jiang z. Vaccine. 2024 Oct 3;42(23):126128. doi: 10.1016/j.vaccine.2024.07.029. Epub 2024 Jul 16. Vaccine. 2024. PMID: 39019659 Free article. No abstract available.
19,340 results
You have reached the last available page of results. Please see the User Guide for more information.